Portfolio

The companies redefining care.

Across two funds, we back early-stage medtech companies whose technologies have the potential to reshape diagnosis, treatment, and the standard of care.

Highcroft Capital — MHIVentures (Fund I)

Fund I — MHIVentures

Realized & Active Investments
Caption Health 7× Return
Geneva Health Solutions 3× Return
Highcroft Capital — MHIV II (Fund II)

A disciplined, physician-led fund.

Fund II was a $2.5M fund backed by 56 Accredited Investor Limited Partners, writing checks of $50K–$250K into early-stage medtech companies. Both Highcroft funds are closed to new investment.

Fund Size
$2.5M
Check Size
$50K – $250K
Limited Partners
56 Accredited Investors
Typical Investment Stage
Seed, Bridge, Series A

The fund employs industry-standard investor management, tracking, compliance, and tax software to ensure streamlined, transparent, and regulatory-compliant operations.

Our Approach

Clinical judgment behind every investment.

Learn how a team of physician investors evaluates and supports the medtech companies redefining care.

Our philosophy